Artelo biosciences announces promising new data on novel non-opioid treatment approach for osteoarthritis pain at the 13th annual musculoskeletal repair and regeneration symposium

Art26.12, the company's lead clinical fatty acid binding protein 5 inhibitor, continues to show positive preclinical results in multiple pain studies art26.12, the company's lead clinical fatty acid binding protein 5 inhibitor, continues to show positive preclinical results in multiple pain studies
ARTL Ratings Summary
ARTL Quant Ranking